GSM symptom outcomes and sexual-function outcomes are separate evidence lanes — the same therapy may improve one and not the other
The AHRQ/PCORI systematic review (46 RCTs) found mostly LOW certainty evidence across symptom-specific treatment pairings. No treatment demonstrated efficacy for vulvovaginal discomfort/irritation or dysuria.
Sexuality during menopause is not a homogeneous experience — partner communication was the central theme across 21 studies in 13 countries
A qualitative meta-synthesis found seven themes including sexual freedom, performative sex as duty, and privilege differentiating outcomes. Neither patients nor providers typically initiate sexual health conversations.
Systemic estrogen increases urinary incontinence risk, while vaginal estrogen does not share this signal and may improve UI when it coexists with GSM
This route distinction is critical for treatment decisions. BMI is a major modifiable risk factor — each 5 kg/m² increase raises UI risk approximately 20%.
Genitourinary syndrome of menopause — the umbrella term for vaginal, urinary, and sexual changes caused by declining estrogen — is chronic and progressive. GSM does not resolve without treatment. Symptoms return approximately 1 month and signs approximately 3 months after discontinuing effective treatment (86).
The fair prevalence estimate is 40-60% of postmenopausal women, though reported ranges span 14-87% depending on the study. Vaginal dryness is reported at 47-100%, dyspareunia at 20-77.6%, and urinary incontinence at 23-50%. Age and time since menopause affect both presence and severity (86).
An important diagnostic note: GSM is a broader term than vulvovaginal atrophy (VVA), but it may reduce diagnostic specificity. Each GSM symptom can have multiple causes requiring differential diagnosis — urinary symptoms may reflect overactive bladder or pelvic floor dysfunction, not only estrogen decline (86).
The Scale of Undertreatment
Treatment Options — GSM Symptoms and Tissue Outcomes
GSM symptom-tissue outcomes (dryness, dyspareunia, maturation index, vaginal pH, visible VVA signs) and sexual-function outcomes (desire, arousal, frequency, global function scores, pain with sexual activity) have different evidence bases. The same therapy may improve one and not the other within the same population over the same follow-up period.
Local Vaginal Estrogen
displays class-effect efficacy across formulations — estradiol tablets (4-10 mcg), softgel inserts, rings, and creams; estriol gels, creams, and inserts; and promestriene. At recommended doses, LET does not raise circulating estradiol above normal postmenopausal levels. Formulation choice is based on patient preference to support compliance. No routine progestogen is needed at recommended doses (86).
Vaginal DHEA
significantly reduces dyspareunia and dryness after 12 weeks, with dual estrogenic-androgenic intracrine activity and without significantly increasing circulating sex steroids (86).
Ospemifene
is now considered a first-line pharmacological option alongside LET, after 5-year VTE safety data showed reassuring results. It has a neutral-to-antagonist effect on breast tissue. Regulatory status differs: EMA permits it after completed breast cancer treatment; FDA considers it contraindicated (86).
Vaginal Laser
has not shown benefit over sham in controlled trials. Regulatory agencies and scientific societies do not support routine clinical use (86).
What the AHRQ/PCORI Systematic Review Shows
For Breast Cancer Survivors
GSM affects up to 70% of breast cancer survivors per ICSM estimates. Women on aromatase inhibitors are more symptomatic than those on tamoxifen (vaginal dryness 57.6% vs 32.4% vs 1.8% in controls). The treatment approach in this population follows a different path: non-hormonal options first, then low or ultra-low-dose local estrogen only after risk-benefit discussion with an oncologist. See the Breast Cancer & HRT section for the full risk framing on vaginal estrogen safety after breast cancer, including recurrence caution for aromatase-inhibitor users (86, 88).
Emerging and Uncertain Options
Soy isoflavones showed a postmenopausal vaginal-dryness signal (SMD -1.88) in a systematic review of 13 trials, but with considerable heterogeneity (I²=97%). A urogenital-symptom improvement was cleaner (SMD -0.33, I²=0%). Dyspareunia and VMS were not statistically significant. The evidence supports a possible dryness/urogenital benefit — not global sexual function or VMS. Women with estrogen-sensitive cancers or on anti-estrogen medication should discuss soy supplementation with their clinician (127, 77).
Probiotics showed large pooled effects for vaginal dryness (SMD -0.95), Nugent score (SMD -0.91), and VMS (SMD -0.96) in a meta-analysis of 7 RCTs, all with I²=0%. Sexual symptoms and somatic symptoms were not significant. However, 41% of included studies had high or critical risk of bias, the systematic review was sponsored by Health & Her (which participated in design, execution, analysis, and interpretation), and 5 of 7 underlying estriol-combination studies were commissioned by the product developer (Medinova/Gynoflor). These are emerging signals requiring substantial confidence discounting (73).
Abnormal Uterine Bleeding — Cross-Reference
Abnormal uterine bleeding during perimenopause is covered in the What to Watch For section (S5), including the distinction between physiologic and red-flag bleeding, AUB process-of-care disparities in US emergency departments, and the association between AUB and comorbid anxiety/depression. If you are experiencing irregular or heavy bleeding, see that section for the evidence on when evaluation is warranted and how care-access patterns differ by race, age, and geography.
Sexual Function — A Separate Evidence Lane
Sexual-function outcomes have a different and generally weaker evidence base than GSM tissue outcomes.
A Cochrane review (36 RCTs, 23,299 women) found that estrogen alone may modestly improve composite sexual-function scores in symptomatic or early postmenopausal women (SMD 0.50, 95% CI 0.04-0.96, 3 studies, n=699, moderate quality). In unselected postmenopausal women, the confidence interval crossed zero. The pooled estrogen-alone effect was significant but with very high heterogeneity (I²=92%). Only 1 of 36 trials evaluated perimenopausal women. None enrolled only women with sexual dysfunction. Only 7 studied sexual function as the primary outcome (22).
In the MsFLASH trial (n=302, mean age 61), did not significantly improve sexual activity frequency or pain severity compared to placebo. However, the parent trial reported that 80% of the estradiol arm versus 65% of the placebo arm experienced "meaningful benefit" (p=0.02) — a quality-of-life signal not explained by more frequent sex or less pain (5).
In a head-to-head trial (n=172), DHEA was significantly superior to vaginal estradiol for dyspareunia in the severe-dyspareunia subgroup (OR 3.4, 95% CI 1.07-10.5), but the overall comparison was near-threshold and not conventionally significant (OR 2.87, p=0.051). Estradiol was superior for objective VVA signs — friability, petechiae, pH, and maturation index (all p<0.001). The trial illustrates why symptom endpoint matters: DHEA favored severe dyspareunia, while estradiol favored objective VVA signs (121).
Sexuality Is Not a Homogeneous Experience
A qualitative meta-synthesis across 21 studies in 13 countries (610 women) found that sexuality during menopause is shaped by relationship dynamics, sexual autonomy, personal history, and cultural context — not by biology alone. Seven themes emerged: fertility/femininity/desirability; performative sex as duty in patriarchal or religious contexts; menopause as sexual freedom; rather no sex than bad sex; partner communication as the central theme; privilege (money, knowledge, autonomy) differentiating outcomes; and the need for knowledge, willingness, and access in any support system (85).
Where communication exists, couples adapt — lubricants, positions, non-penetrative sex, more time. Where communication is absent, sex becomes "sorrow or conflict." A vicious circle can develop: painful sex leads to decreased desire, then avoidance, then worse relationship dynamics. Women with a prior positive view of sex tend to seek solutions; those with prior negative experiences are more likely to give up.
Some women experience menopause as sexual liberation — freedom from menstruation, contraception, and pregnancy worry. Some report better sex with age through confidence, experience, and self-knowledge. Neither patients nor healthcare providers typically initiate conversations about sexual health during menopause — a "two-way taboo" (85).
Urinary Health
Urinary incontinence affects an estimated 45-50% of menopausal women. There is no sharp prevalence jump at menopause itself — age, BMI, parity, and prior urinary incontinence during pregnancy are all heavily influential. Stress urinary incontinence tends to predominate before and early after menopause, while urgency and mixed incontinence become more common with age and time since menopause. BMI is a major modifiable risk factor: each 5 kg/m² increase raises UI risk by approximately 20% (overweight OR 1.27, obese OR 1.60, BMI ≥35 OR 1.85) (97).
A critical distinction for treatment: systemic estrogen is associated with increased urinary incontinence risk in postmenopausal women, while does not share this signal and may improve UI symptoms when UI coexists with GSM (97). Per ICS guidance summarized in the review, pelvic floor muscle training is positioned as the first step, with PFMT plus intravaginal estriol showing better results than estriol alone in cited studies.
UTI Prevention
Questions to Bring to Your Doctor
"I have vaginal dryness and pain with sex. Which treatment — local estrogen, DHEA, or ospemifene — makes the most sense given my medical history?"
"I'm getting more UTIs since menopause. Is there evidence for vaginal estrogen to prevent them?"
"I have urinary incontinence. Should I be using local vaginal estrogen, pelvic floor therapy, or both — and does systemic hormone therapy carry a different risk for bladder symptoms?"
"Sex has changed for me during menopause. Is this a tissue problem, a relationship dynamic, or both — and what does the evidence say about treatment for each?"
"I had breast cancer. The FDA and EMA disagree about ospemifene. What does my oncologist recommend for my specific situation?"
